Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AB267. Association of genetic polymorphism of CCNE1 and RIP2 with bladder cancer risk

ABSTRACT:

Background

A single nucleotide polymorphism is identified at CCNE1 and RIP2. We evaluated the relationship between the CCNE1 or RIP2 and the risk, clinic stage and pathologic grade of bladder cancer.

Methods

Peripheral venous blood samples were obtained from 176 patients with bladder cancer and 210 controls with no cancers of any kinds. The diagnoses, pathological stage of bladder cancer were all determined according to the pathological reports of transurethral bladder cancer resection and radical cystectomy. The polymorphism was determined by polymerase chain reaction and sequencing methods.

Results

(I) The distribution of the CCNE1 and RIP 2 allele frequencies among control subjects was in Hardy-Weinberg equilibrium; (II) the frequency of CCNE1 (rs8102137) variant allele was significantly higher in the case subjects (40.91%) than in controls (30.95%) (P<0.05, OR=1.54, 95% CI 1.02–2.45). The frequency of CCNE1 (rs8102137) variant allele was significantly higher in the case subjects (72.73%) than in controls (62.38%) (P<0.05, OR=1.61, 95% CI, 1.04–2.48); (III) there was no association between the CCNE1 (rs8102137) and RIP2 (rs42490). Polymorphisms and Pathological grade and clinical stage of bladder cancer.

Conclusions

The CCNE1 (rs8102137) and RIP2 (rs42490) polymorphism have interaction in occurrence of bladder cancer process, no association with Pathological grade and clinical stage of bladder cancer.

SUBMITTER: Liang E

PROVIDER: S-EPMC4842531 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Association between Pri-miR-34b/c rs4938723 polymorphism and bladder cancer risk.

Project description:Several studies examined the impact of miR-34b/c rs4938723 polymorphism and cancer risk, but the findings are inconsistent. However, no study has been conducted to inspect the impact of miR-34b/c polymorphism on bladder cancer. This study aimed to assess possible association between rs4938723 polymorphism and bladder cancer risk. This case-control study was done on 136 pathologically proven bladder cancer patients and 144 controls. Genotyping of Pri-miR-34b/c rs4938723 polymorphism was achieved by using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. Our findings did not show any statistically significant differences in genotype and allele frequencies between bladder cancer and controls. Larger sample sizes with diverse ethnicities are required to validate our findings.

| S-EPMC6352879 | biostudies-literature

Association between interleukin-22 genetic polymorphisms and bladder cancer risk.

Project description:The cytokine interleukin-22 (IL-22), which is produced by T cells and natural killer cells, is associated with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in bladder cancer has not been investigated.A prospective hospital-based case-control study comprising 210 patients with pathologically proven bladder cancer and 210 age- and gender-matched healthy controls was conducted. The genotypes of 3 common polymorphisms (-429 C/T, +1046 T/A and +1995 A/C) of the IL-22 gene were determined with fluorogenic 5' exonuclease assays.Patients with bladder cancer had a significantly higher frequency of the IL-22 -429 TT genotype [odds ratio (OR)=2.04, 95% confidence interval (CI)=1.19, 3.49; p=0.009] and -429 T allele (OR=1.42, 95% CI=1.08, 1.87; p=0.01) than the healthy controls. These findings were still significant after a Bonferroni correction. When stratifying according to the stage of bladder cancer, we found that patients with superficial bladder cancer had a significantly lower frequency of the IL-22 -429 TT genotype (OR=0.48, 95% CI=0.23, 0.98; p=0.04). When stratifying according to the grade and histological type of bladder cancer, we found no statistical association. The IL-22 +1046 T/A and IL-22 +1995 A/C gene polymorphisms were not associated with the risk of bladder cancer.To the authors' knowledge, this is the first report documenting that the IL-22 -429 C/T gene polymorphism is associated with bladder cancer risk. Additional studies are required to confirm this finding.

| S-EPMC4602377 | biostudies-literature

The association between rs9642880 gene polymorphism and bladder cancer risk: a meta-analysis.

Project description:Previous studies had researched the relationship between rs9642880 gene polymorphism and bladder cancer risk, but the results remained unclear. The comprehensive meta-analysis was performed to clarify this possible association. Relevant articles were searched from Pubmed, Embase and web of science. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated to assess the strength of the association. The assessment of publication bias was conducted by Begg's funnel plots and Egger's regression test. A total of 7 casecontrol studies involving 4072 cases and 4898 controls were included in our study. Overall, an obvious relationship between rs9642880 polymorphism and increased risk of bladder cancer were detected in all models. Besides, the positive results were observed among both Caucasians and Asians when stratified by ethnicity. Moreover, when stratified by genotyping method, the significant results were detected in all genotyping methods except Sequenom. In addition, in the subgroup analysis by source of control, significant results were detected in both population and hospital based controls. This present meta-analysis with accurate and reliable results indicated that the T allele of SNP rs9642880 confers susceptibility to bladder cancer in both Asian and Caucasian populations.

| S-EPMC4723781 | biostudies-literature

Genetic association between leptin-2548G/A polymorphism and risk of cancer: a meta analysis.

Project description:OBJECTIVE: Abundance of evidence implicated that leptin may play a decisive role in cancer occurrence, but the reported results varied across the individually published studies. The objective of this study is to access to what extent the extensively studied -2548G/A polymorphism of LEP gene acts on the onset of multiple cancers. METHODS: Eligible studies included in this meta-analysis were identified electronically in PubMed and Embase, and manually in relevant literature. Crude odds ratio (OR) with corresponding 95% confidence interval (CI) was calculated to estimate the risk of cancer associated with the -2548G/A polymorphism. RESULTS: 12 association studies with a total of 5,618 cancer cases and 6,509 healthy controls were pooled into this meta-analysis. The results revealed that compared with the G allele, the A allele was associated with modestly increased risk of overall cancer (OR, 1.21; 95% CI, 1.02-1.44). Following further stratified analyses, a borderline association was indicated in prostate cancer (OR, 1.18; 95% CI, 1.00-1.39), breast cancer (OR, 1.11; 95% CI, 1.00-1.22) and Caucasians (OR, 1.19; 95% CI, 1.00-1.41). CONCLUSIONS: This meta-analysis reveals that the A allele of -2548G/A polymorphism may be a determinant of cancer development.

| S-EPMC4358471 | biostudies-other

Genetic association between CD95 rs2234767 polymorphism and cervical cancer risk: a meta analysis.

Project description:BackgroundCD95 rs2234767 polymorphism in the promotor region of CD95 gene has been implicated in several studies of cervical cancer. However, the results have not been conclusively established.ObjectiveThe main aim of this study was to deal with the controversy with respect to the correlation between CD95 rs2234767 polymorphism and risk of cervical cancer through a meta-analysis.MethodsAssociation studies that pertain to CD95 rs2234767 polymorphism and risk of cervical cancer were identified up to May 26, 2014. ORs and 95% CIs were calculated assuming AA versus GG, AA + AG versus GG, AA versus AG + GG, A versus G and AG versus GG genetic models.ResultsA total of 5 case-control studies were included in this meta-analysis. Overall, no significant effect modification of cervical cancer risk was revealed either at the genotypic or the allelic level for CD95 rs2234767 polymorphism. This null association persisted in the stratified analysis of Asian population.ConclusionsThese findings revealed that CD95 rs2234767 polymorphism may not act as a causative agent of cervical cancer. Further evidence is needed to confirm our findings.

| S-EPMC4402820 | biostudies-literature

Association of Glutathione S-transferase gene polymorphism with bladder Cancer susceptibility.

Project description:BackgroundWe conducted a meta-analysis to evaluate the relationship between the glutathione S-transferase ?1 (GSTM1)- and glutathione S-transferase ?1 (GSTT1)- null genotypes and susceptibility to bladder cancer.MethodsWe identified association reports from the databases of PubMed, Embase, the Cochrane Library and the China Biological Medicine Database (CBM disc) on July 1, 2017 and synthesized eligible investigations. Results were expressed using odds ratios (ORs) for dichotomous data, and we also calculated 95% confidence intervals (CIs).ResultsIn this meta-analysis, we found that the GSTM1-null genotype was associated with bladder cancer risk in the overall population, and individually in whites, Africans and Asians (overall population: OR?=?1.40, 95% CI: 1.31-1.48, P<0.00001; whites: OR?=?1.39, 95% CI: 1.26-1.54, P<0.00001; Africans: OR?=?1.54, 95% CI: 1.16-2.05, P?=?0.003; Asians: OR?=?1.45, 95% CI: 1.33-1.59, P<0.00001). The GSTT1-null genotype was associated with bladder cancer risk in the overall population, but not in whites, in Africans or Asians (overall population: OR?=?1.11, 95% CI: 1.01-1.22, P?=?0.03; whites: OR?=?1.16, 95% CI: 0.99-1.36, P?=?0.07; Africans: OR?=?1.07, 95% CI: 0.65-1.76, P?=?0.79; Asians: OR?=?1.05, 95% CI: 0.91-1.22, P?=?0.51). Interestingly, a dual-null GSTM1-GSTT1 genotype was associated with bladder cancer risk in the overall population and in Asians (overall population: OR?=?1.48, 95% CI: 1.15-1.92, P?=?0.002; Asians: OR?=?1.62, 95% CI: 1.15-2.28, P?=?0.006). In conclusion, the GSTM1-null, GSTT1-null and dual-null GSTM1-GSTT1 genotypes might be associated with the onset of bladder cancer, but additional genetic-epidemiological studies should be conducted to explore this association further.

| S-EPMC6233535 | biostudies-literature

Association between the TACC3 rs798766 Polymorphism and Risk of Urinary Bladder Cancer: A Synthesis Based on Current Evidence.

Project description:BackgroundA possible association between the TACC3 rs798766 polymorphism and urinary bladder cancer risk has been indicated in published literature. We performed this meta-analysis as a synthesis of all relevant data to summarize currently available evidence and to provide estimation with increased precision.MethodsEMBASE, PubMed, Google Scholar, and Wanfang Data were searched. "rs798766" and "urinary bladder cancer" were used as the search terms. A total of 6 eligible studies were identified, in which 8194 cases and 50,165 controls were investigated. Meta-analysis was performed using extracted data. Subgroup analysis by ethnicity was also performed. Population attributable risk (PAR) was calculated.ResultsWe found a significant association between rs798766[T] and increased risk of bladder cancer, allelic[T] OR = 1.27, 95%CI = 1.20-1.33. Subgroup analysis by ethnicity revealed similar results, allelic[T] OR = 1.24, 95%CI = 1.17-1.32 in Caucasian subjects and allelic[T] OR = 1.33, 95%CI = 1.21-1.46 in Asian subjects. PAR based on pooled allelic ORs and the frequency of the risk allele in control subjects was 4.63% in the overall population and 3.92% in Asians and 4.36% in Caucasians.Conclusionrs798766 is associated with increased risk of bladder cancer, and no ethnic difference was found.

| S-EPMC5474538 | biostudies-literature

Genetic susceptibility to bladder cancer risk and outcome.

Project description:Bladder cancer is an excellent model for studying genetic susceptibility and gene-environment interaction in cancer etiology. The candidate gene approach found NAT2 slow acetylator and GSTM1-null genotypes to be bladder cancer susceptibility loci and also demonstrated interactions between these two genotypes and smoking in modulating bladder cancer risk. Recent genome-wide association studies identified at least eight novel genetic susceptibility loci for bladder cancer. Genetic determinants of clinical outcomes have been inconclusive. The future directions are to identify more genetic susceptibility loci for bladder cancer risk and outcome through a genome-wide association study approach, identify the causal genes and variants, study the biological mechanisms underlying the association between the causal variants and bladder cancer risk, detect gene-environment interactions and incorporate genetic knowledge into clinically applicable risk prediction models to benefit patients and public health.

| S-EPMC3172962 | biostudies-literature

Coffee consumption, genetic susceptibility and bladder cancer risk.

Project description:OBJECTIVE:We evaluated the bladder cancer risk associated with coffee consumption in a case-control study in Spain and examined the gene-environment interactions for genetic variants of caffeine-metabolizing enzymes. METHODS:The analyses included 1,136 incident cases with urothelial carcinoma of the urinary bladder and 1,138 controls. Odds ratios (OR) and 95% confidence intervals (CI) were adjusted for area, age, gender, amount of cigarette smoking, and years since quitting among former smokers. RESULTS:The OR (95% CI) for ever consumed coffee was 1.25 (0.95-1.64). For consumers of 1, 2, 3, and 4 or more cups/day relative to never drinkers, OR were, respectively, 1.24 (0.92-1.66), 1.11 (95% CI 0.82-1.51), 1.57 (1.13-2.19), and 1.27 (0.88-1.81). Coffee consumption was higher in smokers compared to never smokers. The OR for drinking at least 4 cups/day was 1.13 (0.61-2.09) in current smokers, 1.57 (0.86-2.90) in former smokers, and 1.23 (0.55-2.76) in never smokers. Gene-coffee interactions evaluated in NAT2, CYP1A2, and CYP2E1-02 and CYP1A1 were not identified after adjusting for multiple testing. CONCLUSION:We observed a modest increased bladder cancer risk among coffee drinkers that may, in part, be explained by residual confounding by smoking. The findings from the gene-coffee interactions need replication in further studies.

| S-EPMC2912840 | biostudies-literature

Possible association between a genetic polymorphism at 8q24 and risk of upper gastrointestinal cancer.

Project description:Over recent years, genome-wide association studies have contributed to our understanding of genetic susceptibility to sporadic cancer. In this study, we assessed the association between upper gastrointestinal cancer risk and four genome-wide association studies-identified single nucleotide polymorphisms (SNPs), implicated earlier in prostate and colorectal cancer susceptibility. Genotyping for each SNP was performed in two independent Caucasian population-based case-control studies. The first study comprised 290 gastric cancer cases and 374 controls. The second study included 185 noncardia gastric cancers, 123 cardia cancers, 158 oesophageal cancers and 209 controls. Odds ratios (ORs) were computed from logistic models and adjusted for potential confounding variables. An inverse association was observed between the SNP rs1447295, located at 8q24, and gastric cancer risk in the first study population (OR=0.63; 95% confidence interval: 0.41-0.97). A positive association was observed for the same SNP and oesophageal squamous cell carcinoma in the second study population (OR=7.43; 95% confidence interval: 1.37-49.98). No significant associations were detected in either study for the three remaining SNPs (rs6983297, rs10505477 and rs719725). Our data represent novel findings on heritable susceptibility to gastric and oesophageal cancer and warrant validation in additional populations.

| S-EPMC3020097 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data